Photoimmunotherapy as an in situ vaccine with PD-1 blockade
Bursting tumour cells with light releases their contents to the immune system; adding immunotherapy might turn a local treatment into a body-wide one.
Cetuximab sarotalocan causes immunogenic cell death and, in animal models, abscopal responses with checkpoint blockade. A phase 2 with pembrolizumab in recurrent HNSCC has been run in the US.
Pages like this
not linked directly; found by shared links- IdeaTurn one tumour into a vaccine to treat all the others
Shares Abscopal effect, Immunogenic cell death, Cold tumours and the immunosuppressive microenvironment, Head and neck squamous cell carcinoma.
- IdeaPick the radiation dose that switches the immune alarm on, not off
Shares Abscopal effect, Immunogenic cell death, Cold tumours and the immunosuppressive microenvironment, Immune checkpoint inhibitors.
- IdeaMechanically pulverise one tumour with ultrasound to wake the immune system
Shares Abscopal effect, Immunogenic cell death, Cold tumours and the immunosuppressive microenvironment, Immune checkpoint inhibitors.
- TechnologyHistotripsy as an immune primer
Shares Abscopal effect, Immunogenic cell death, Immune checkpoint inhibitors.
- InstitutionShandong Cancer Hospital and Institute
Shares Abscopal effect, Head and neck squamous cell carcinoma, Immune checkpoint inhibitors.
- TechnologyLattice and GRID radiotherapy
- TrialKEYNOTE-177
Shares Cold tumours and the immunosuppressive microenvironment, Pembrolizumab, Immune checkpoint inhibitors.
- TechnologyRadiodynamic therapy and radiosensitising nanoparticles
Shares Photoimmunotherapy & photodynamic therapy, Head and neck squamous cell carcinoma.